NEW YORK (GenomeWeb News) — Celera today said it will collaborate with Merck & Co. to develop molecular diagnostics for the drug maker to use in it clinical trials, which could potentially be used as companion diagnostics for Merck’s cancer drugs.
Terms of the deal, which is expected to wrap up at the end of Celera’s fiscal year 2008, call for the Applera unit to create assays based on gene-expression profiles that Merck identifies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.